NeoGenomics, Inc. Launches c-Met CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

Published: 2025-05-22 08:05:22 ET NEO

Published on 05/22/2025 at 08:05

NeoGenomics, Inc. announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay. The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour turnaround time. The c-MET CDx forNSCLC assay detects c-Met protein overexpression, a biomarker observed in up to 50% of patients with advanced NSCLC.

It is designed to help identify patients who may be eligible for newly approved targeted therapies, including EMRELIS?? (telisotuzumab vedotin-tllv), which was recently approved by the U.S. Food and Drug Administration (FDA). Key features of NeoGenomics' assay include: Companion Diagnostic Indication: Developed in accordance with FDA guidance and validated for use with MET-targeted therapies; Fast Turnaround: Delivers results within 48 hours to enable timely, informed clinical decisions; Validated Performance: Designed for use with tumor tissue samples to detect MET protein overexpression; Integrated NSCLC Offering: Complements NeoGenomics' broader PanTracer??

portfolio, including genomic and immuno-oncology markers. The c-MET CD x for NSCLC assay is now available as part of NeoGenomics' comprehensive NSCLC testing portfolio. Its addition supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.